Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 320 Records) |
| Query Trace: Neoplasms and UGT1A1[original query] |
|---|
| UGT1A1 regulatory variant with potential effect on efficacy of HIV and cancer drugs commonly prescribed in South Africa. Pharmacogenomics 2021 9 22 (15): 963-972. Mathew Jenny Mary, Mpangase Phelelani Thokozani, Sengupta Dhriti, Kwenda Stanford, Mavri-Damelin Demetra, Ramsay Michè |
| Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer. Cancer science 2021 7 112 (11): 4669-4678. Iwasa Satoru, Muro Kei, Morita Satoshi, Park Young Suk, Nakamura Masato, Kotaka Masahito, Nishina Tomohiro, Matsuoka Hiroshi, Ahn Joong Bae, Lee Keun-Wook, Hong Yong Sang, Han Sae Won, Cho Sang-Hee, Zhang Dong-Sheng, Fang Wei-Jia, Bai Li, Yuan Xiang-Lin, Yuan Ying, Yamada Yasuhide, Sakamoto Junichi, Kim Tae W |
| Dosage Adjustment of Irinotecan in Patients with UGT1A1 Polymorphisms: A Review of Current Literature. Innovations in pharmacy 2021 5 11 (3): . Argevani Lia, Hughes Caren, Schuh Michael |
| UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers 2021 4 13 (7): . Nelson Ryan S, Seligson Nathan D, Bottiglieri Sal, Carballido Estrella, Cueto Alex Del, Imanirad Iman, Levine Richard, Parker Alexander S, Swain Sandra M, Tillman Emma M, Hicks J Kev |
| Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer. Tumori 2021 12 107 (6): 536-541. Seto Zenta, Takata Naoki, Murayama Nozomu, Tokui Kotaro, Okazawa Seisuke, Kambara Kenta, Imanishi Shingo, Miwa Toshiro, Hayashi Ryuji, Matsui Shoko, Inomata Minehi |
| DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols. British journal of clinical pharmacology 2021 Nov . Božina Nada, Bili? Ivan, Ganoci Lana, Šimi?evi? Livija, Pleština Stjepko, Lešnjakovi? Lucija, Trkulja Vladim |
| Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients. British journal of cancer 2021 Oct . Karas Spinel, Etheridge Amy S, Nickerson Deborah A, Cox Nancy J, Mohlke Karen L, Cecchin Erika, Toffoli Giuseppe, Mathijssen Ron H J, Forrest Alan, Bies Robert R, Innocenti Federi |
| Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer. Scientific reports 2022 9 12 (1): 15574. Irisawa Ai, Takeno Misaki, Watanabe Kazuo, Takahashi Hideaki, Mitsunaga Shuichi, Ikeda Masafu |
| Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 2022 Aug 8 (1): 98. Rugo Hope S, Tolaney Sara M, Loirat Delphine, Punie Kevin, Bardia Aditya, Hurvitz Sara A, O'Shaughnessy Joyce, Cortés Javier, Diéras Véronique, Carey Lisa A, Gianni Luca, Piccart Martine J, Loibl Sibylle, Goldenberg David M, Hong Quan, Olivo Martin, Itri Loretta M, Kalinsky Kev |
| Risk Factors for Septic Shock After Irinotecan-Containing Chemotherapy: An Exploratory Case-Control Study. Drugs in R&D 2022 Aug . Umemiya Maki, Inayama Yoshihide, Nakatani Eiji, Ito Kenta, Tsuji Mitsuru, Yoshida Teruki, Yu Sae, Gou Rei, Horikawa Naoki, Tani Hirohiko, Kosaka Ken |
| Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis. Clinical and translational science 2022 May . Atasilp Chalirmporn, Biswas Mohitosh, Jinda Pimonpan, Nuntharadthanaphong Nutthan, Rachanakul Jiratha, Hongkaew Yaowaluck, Vanwong Natchaya, Saokaew Surasak, Sukasem Chonlaph |
| The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer. International journal of clinical oncology 2022 5 27 (8): 1331-1339. Satake Tomoyuki, Morizane Chigusa, Maruki Yuta, Ohba Akihiro, Nagashio Yoshikuni, Kondo Shunsuke, Hijioka Susumu, Ueno Hideki, Okusaka Taku |
| Clinical Outcomes of Patients with Peritoneal Metastasis-Only Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI Through Irinotecan Dose Escalation According to UGT1A1 Polymorphism: Compared to Liver Metastasis-Only, and Lung Metastasis-Only. Cancer management and research 2022 5 14 1541-1549. Li Ching-Chun, Chang Tsung-Kun, Chen Yen-Cheng, Tsai Hsiang-Lin, Huang Ching-Wen, Su Wei-Chih, Ma Cheng-Jen, Yin Tzu-Chieh, Chen Po-Jung, Wang Jaw-Yu |
| Characteristics and Clinical Implication of UGT1A1 Heterozygous Mutation in Tumor. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2022 3 25 (3): 137-146. Li Qian, Sun Tao, Zhang Hua, Liu Wei, Xiao Yu, Sun Hongqi, Yin Wencheng, Yao Yanhong, Gu Yangchun, Liu Yan'e, Yi Fumei, Wang Qiqi, Yu Jinyu, Cao Baoshan, Liang |
| UGT1A1 Gene Polymorphism Contributes as a Risk Factor for Lung Cancer: A Pilot Study with Patients from the Amazon. Genes 2022 3 13 (3): . Pereira Esdras E B, Leitão Luciana P C, Andrade Roberta B, Modesto Antônio A C, Fernandes Bruno M, Burbano Rommel M R, Assumpção Paulo P, Fernandes Marianne R, Guerreiro João F, Santos Sidney E B Dos, Santos Ney P C D |
| Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma. Cancer medicine 2022 Mar . Imaya Masayuki, Muramatsu Hideki, Narita Atsushi, Yamamori Ayako, Wakamatsu Manabu, Yoshida Taro, Miwata Shunsuke, Narita Kotaro, Ichikawa Daisuke, Hamada Motoharu, Nishikawa Eri, Kawashima Nozomu, Nishio Nobuhiro, Kojima Seiji, Takahashi Yoshiyu |
| Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study. Cancers 2022 3 14 (5): . Keum Jiyoung, Lee Hee Seung, Jo Jung Hyun, Chung Moon Jae, Park Jeong Youp, Park Seung Woo, Song Si Young, Bang Seungm |
| Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy. Oncology research 2022 Feb . Tsai Hsiang-Lin, Chen Yen-Cheng, Yin Tzu-Chieh, Su Wei-Chih, Chen Po-Jung, Chang Tsung-Kun, Li Ching-Chun, Huang Ching-Wen, Wang Jaw-Yu |
| Association of Inherited Genetic Factors With Drug-Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia. JAMA network open 2022 12 5 (12): e2248803. Yang Wenjian, Karol Seth E, Hoshitsuki Keito, Lee Shawn, Larsen Eric C, Winick Naomi, Carroll William L, Loh Mignon L, Raetz Elizabeth A, Hunger Stephen P, Winter Stuart S, Dunsmore Kimberly P, Devidas Meenakshi, Relling Mary V, Yang Jun |
| Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan. European journal of human genetics : EJHG 2022 11 . Hulshof Emma C, Deenen Maarten J, Nijenhuis Marga, Soree Bianca, de Boer-Veger Nienke J, Buunk Anne-Marie, Houwink Elisa J F, Risselada Arne, Rongen Gerard A P J M, van Schaik Ron H N, Touw Daan J, van der Weide Jan, van Westrhenen Roos, Deneer Vera H M, Guchelaar Henk-Jan, Swen Jesse |
| Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. Cancer medicine 2022 10 . Kanesada Kou, Tsunedomi Ryouichi, Hazama Shoichi, Ogihara Hiroyuki, Hamamoto Yoshihiko, Shindo Yoshitaro, Matsui Hiroto, Tokumitsu Yukio, Yoshida Shin, Iida Michihisa, Suzuki Nobuaki, Takeda Shigeru, Ioka Tatsuya, Nagano Hiroa |
| Genotyping of UGT1A1*80 as an Alternative to UGT1A1*28 Genotyping in Spain. Pharmaceutics 2022 10 14 (10): . Bravo-Gómez Adrián, Salvador-Martín Sara, Zapata-Cobo Paula, Sanjurjo-Sáez María, López-Fernández Luis Andr |
| Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 2022 Jul 46 (4): 224-233. Miarons Marta, Riera Pau, García-Gil Sara, Gutiérrez-Nicolás Fernan |
| The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients. Genomics & informatics 2022 Sep 20 (3): e29. Lee Choong-Kun, Chon Hong Jae, Kwon Woo Sun, Ban Hyo-Jeong, Kim Sang Cheol, Kim Hyunwook, Jeung Hei-Cheul, Chung Jimyung, Rha Sun You |
| Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. Cancer 2022 1 128 (8): 1649-1657. Reizine Natalie M, Danahey Keith, Truong Tien M, George David, House Larry K, Karrison Theodore G, van Wijk Xander M R, Yeo Kiang-Teck J, Ratain Mark J, O'Donnell Peter |
| Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study. Thoracic cancer 2023 9 . Hiromi Tomono, Hirokazu Taniguchi, Minoru Fukuda, Takaya Ikeda, Seiji Nagashima, Kazumasa Akagi, Sawana Ono, Yasuhiro Umeyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto, Yasushi Hisamatsu, Ryotaro Morinaga, Ryuta Tagawa, Ryosuke Ogata, Yosuke Dotsu, Hiroaki Senju, Hiroshi Soda, Katsumi Nakatomi, Fumiko Hayashi, Nanae Sugasaki, Akitoshi Kinoshita, Hiroshi Muk |
| Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1. Clinical pharmacokinetics 2023 9 . Mirjam de With, Leni van Doorn, Esmay Kloet, Anne van Veggel, Maja Matic, Micha J de Neijs, Esther Oomen-de Hoop, Esther van Meerten, Ron H N van Schaik, Ron H J Mathijssen, Sander Bi |
| Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer. Genetic testing and molecular biomarkers 2023 5 27 (5): 133-141. Zineb Aoullay, Andrew Smith, Meriem Slaoui, Ihssane El Bouchikhi, Hassan Ghazal, Najib Al Idrissi, Bouchra Meddah, Kara L Lynch, Yahia Cherrah, Alan H B |
| A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer. Journal of gastrointestinal oncology 2023 5 14 (2): 663-675. Shigeo Higami, Masaya Mukai, Daiki Yokoyama, Syuji Uda, Rin Abe, Nana Mamuro, Kyoko Kishima, Sayuri Hasegawa, Takayuki Tajima, Eiji Nomura, Hiroyasu Makuuc |
| Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study group. Journal of experimental & clinical cancer research : CR 2023 1 42 (1): 21. Junk Stefanie V, Schaeffeler Elke, Zimmermann Martin, Möricke Anja, Beier Rita, Schütte Peter, Fedders Birthe, Alten Julia, Hinze Laura, Klein Norman, Kulozik Andreas, Muckenthaler Martina U, Koehler Rolf, Borkhardt Arndt, Vijayakrishnan Jayaram, Ellinghaus David, Forster Michael, Franke Andre, Wintering Astrid, Kratz Christian P, Schrappe Martin, Schwab Matthias, Houlston Richard S, Cario Gunnar, Stanulla Mart |
- Page last reviewed:Feb 1, 2023
- Page last updated:Sep 29, 2023
- Content source: